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Abstract
Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies
to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of
limited efficacy in this patient population. Human monoclonal antibody HCV1 recognizes a highly-conserved linear epitope
of the HCV E2 envelope glycoprotein (amino acids 412–423) and neutralizes a broad range of HCV genotypes. In a
chimpanzee model, a single dose of 250 mg/kg HCV1 delivered 30 minutes prior to infusion with genotype 1a H77 HCV
provided complete protection from HCV infection, whereas a dose of 50 mg/kg HCV1 did not protect. In addition, an
acutely-infected chimpanzee given 250 mg/kg HCV1 42 days following exposure to virus had a rapid reduction in viral load
to below the limit of detection before rebounding 14 days later. The emergent virus displayed an E2 mutation (N415K/D)
conferring resistance to HCV1 neutralization. Finally, three chronically HCV-infected chimpanzees were treated with a single
dose of 40 mg/kg HCV1 and viral load was reduced to below the limit of detection for 21 days in one chimpanzee with
rebounding virus displaying a resistance mutation (N417S). The other two chimpanzees had 0.5–1.0 log10 reductions in viral
load without evidence of viral resistance to HCV1. In vitro testing using HCV pseudovirus (HCVpp) demonstrated that the
sera from the poorly-responding chimpanzees inhibited the ability of HCV1 to neutralize HCVpp. Measurement of antibody
responses in the chronically-infected chimpanzees implicated endogenous antibody to E2 and interference with HCV1
neutralization although other factors may also be responsible. These data suggest that human monoclonal antibody HCV1
may be an effective therapeutic for the prevention of graft infection in HCV-infected patients undergoing liver
transplantation.
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Introduction
More than 180 million people worldwide are infected with
hepatitis C virus (HCV) [1,2] with over 80% developing chronic
disease marked by progressive hepatitis, fibrosis and cirrhosis that
often results in liver failure [3,4], requiring transplantation.
Unfortunately nearly all donor allografts transplanted into HCV-
positive patients become infected with HCV in the early post-
transplant period. Standard treatment with interferon–alpha (IFN–
a) and ribavirin is poorly tolerated and of limited efficacy in liver
transplant recipients [5–8] and the recently licensed protease
inhibitors have not been extensively studied in this population.
Many lines of evidence suggest broadly-neutralizing antibody
preparations may protect from infection with HCV. Before the
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identification of HCV as the primary cause of non-A, non-B
hepatitis, several randomized trials demonstrated that immune
serum globulin (ISG) prevented non-A, non-B hepatitis following
blood transfusion or sexual exposure [9–11]. More recent studies
suggest that an early neutralizing antibody response may assist in
controlling HCV in the acute phase of infection [12]; however,
polyclonal (Civacir) [13] and monoclonal antibody (HCV-
AbXTL68) [14] have been tested for efficacy in preventing allograft
infection in humans without success possibly due to insufficient
dose or neutralizing potency. Furthermore, hepatitis B immune
globulin (HBIG) and cytomegalovirus (CMV) immune globulin
(Cytogam) have both been used successfully to prevent hepatitis B
virus (HBV) and CMV infection, respectively, after liver trans-
plantation [15,16]. In both instances, combination of antibody
plus small molecule anti-viral treatment has been shown to be
most effective. Lastly, receipt of HBIG preparations containing
anti-HCV antibody was correlated with reduced risk of HCV
recurrence in patients undergoing liver transplantation [17].
There is clinical precedence, therefore, for the use of antibody-
based therapies to prevent recurrence of viral hepatitis after liver
transplantation.
HCV is a member of the Flaviviridae family and contains a
9.6 kb positive-stranded RNA genome which encodes a single
polypeptide that is cleaved post-translationally into at least ten
different proteins. The major HCV surface glycoproteins, E1 and
E2, form a non-covalent heterodimer that mediates viral entry into
target hepatocytes [18]. Defective lentivirus pseudotyped with E1/
E2 envelope glycoproteins (HCVpp) has been shown to infect
hepatocytes [19,20] and HCVpp has become a standard model for
studying HCV entry inhibitors. Numerous cellular co-receptors
including CD81 [21], claudin-1 [22], occludin [23], scavenger
receptor class B type I [24] and others [25] have been identified
and shown to play essential roles in the interaction of HCV
envelope glycoproteins with hepatocytes. The E2 glycoprotein has
been shown to directly interact with cellular receptors [25] and
provides an attractive target for monoclonal antibody neutraliza-
tion.
HCV1 is a human monoclonal antibody isolated using HuMAb
mouse (Medarex, Inc., a wholly owned subsidiary of Bristol-Myers
Squibb) technology by immunizing with soluble E2 envelope
glycoprotein consisting of amino acids 384–660 of E2 [26]. HCV1
recognizes amino acids 412–423 of the HCV E2 envelope
glycoprotein (E2 epitope I), a conserved linear epitope in the N-
terminus of E2. HCV1 neutralizes a broad range of HCV
genotypes (1a, 1b, 2b, 3a and 4a) using HCVpp [26] as well as cell
culture-infectious HCV (HCVcc) JFH1/J6 genotype 2a [27].
Alanine scanning mutagenesis has identified positions 413 and 420
as critical for HCV1 binding. These residues are essentially
invariable in the Los Alamos HCV sequence database suggesting
that changes at these positions are detrimental to the virus. Of
interest, antibody response to E2 amino acids 412–423 in
chronically-infected HCV patients has been shown to be quite
low or nonexistent [28] and nearly all E2 antibodies isolated from
infected humans have been directed against conformational
epitopes.
Chimpanzees are the only animal other than humans that are
permissive to HCV infection and remain the only natural
experimental model of HCV infection although expense and
ethical concerns limit their use. The chimpanzee provides a model
for prevention of initial infection with HCV in the presence of a
fully competent immune system that closely models that of
humans, an important criteria for the evaluation of a human
monoclonal antibody. Also, the levels of HCV replication in
chimpanzee are significantly high enough to allow meaningful
evaluation of entry inhibitors such as monoclonal antibodies. The
infectious inoculum for transmitting HCV to chimpanzees has
been carefully characterized [29]. Typically, animals develop
viremia shortly after exposure to HCV and can develop long-term
infection just as seen in humans. However, the rate at which
exposed chimpanzees develop chronic infection is lower than that
seen for humans. Chimpanzees have been used to demonstrate
that polyclonal antibody has the capacity to prevent initial HCV
infection; however, the antibody preparation had to be premixed
with the viral inoculum to have a protective effect [30–32]. When
immunoglobulin containing HCV antibodies were given to
chimpanzees shortly after infection as post-exposure prophylaxis,
clinical disease was delayed [30]. To our knowledge, no antibody
(monoclonal or polyclonal) has ever protected a chimpanzee from
initial infection when administered to the chimpanzee prior to
viral inoculation. On the whole, chimpanzees are the most
appropriate model for the study of HCV-directed human
monoclonal antibody therapeutics and may also provide valuable
toxicology data that can assess acceptability for human studies.
To determine the potential of HCV1 as a therapeutic for the
prevention of HCV infection, chimpanzees were infused with
either 50 mg/kg or 250 mg/kg HCV1 followed 30 minutes later
with exposure to HCV H77 genotype 1a. HCV1, given at
250 mg/kg, prevented HCV infection of a chimpanzee. Also,
HCV1 reduced the viral load of both an acutely-infected and long-
term chronically-infected chimpanzee to below the limit of
detection for 7 to 21 days followed by a rebound in viral titer.
Rebounding virus was shown to harbor mutations in the 412–423
epitope that conferred resistance to HCV1 neutralization by
preventing HCV1 binding to the E2 glycoprotein. Interestingly,
two chronically-infected chimpanzees only modestly responded to
HCV1 treatment and preliminary experiments suggested that
components in the chimpanzee sera inhibited the effectiveness of
HCV1 neutralization.
Results
HCV1 blocks E2 interaction with CD81
HCV1 neutralizes HCVpp pseudotyped with E1/E2 derived
from a diverse group of genotypes but the mechanism of
neutralization had not been determined [26]. Numerous antibod-
ies have been shown to block interaction of E2 with CD81 and this
Author Summary
The majority of individuals infected with hepatitis C virus
(HCV) become chronically infected and many go on to
develop liver failure requiring liver transplantation. Unfor-
tunately, the transplanted liver becomes infected with HCV
in nearly 100% of transplant patients. Current treatments
for HCV are poorly tolerated after liver transplantation and
graft health is compromised by infection. We have
developed a monoclonal antibody called HCV1 that blocks
HCV from infecting liver cells in culture. Using chimpan-
zees as a model for HCV infection, we demonstrate that
HCV1 has the ability to prevent HCV infection. We also
show that HCV1 can treat chimpanzees chronically
infected with HCV and reduce plasma viral load to below
the level of detection for a period of 7 to 21 days. The virus
that reemerges in the treated chimpanzees was resistant
to HCV1 neutralization demonstrating target engagement.
Given the ability of HCV1 to protect chimpanzees from
HCV infection, we speculate that HCV1 may be beneficial
in HCV- infected patients undergoing liver transplant.
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effect correlated with HCV neutralization. The large extracellular
loop (LEL) of CD81 was expressed in E. coli, purified and coated
on ELISA plates. A soluble version of E2 comprising amino acids
384–660 (E2660) containing a (His)6 epitope tag was produced in
CHO cells, purified and quantitated. E2660 was incubated with
varying concentrations of antibody and the mixture was applied to
the CD81 LEL-coated ELISA plates. Binding of E2660 to CD81
LEL was detected using an anti-(His)6 antibody and the results,
graphed as percent inhibition of the CD81 LEL/E2660 interaction,
are shown in Figure 1. HCV1 was able to inhibit E2660
interaction with CD81 LEL (.90% at the highest antibody
concentrations tested) whereas an irrelevant human antibody had
no impact on binding. These results demonstrate that HCV1 likely
neutralizes HCV by blocking E2 interaction with the CD81
receptor found on target cells.
HuMAb HCV1 protects a chimpanzee from initial
challenge with HCV
HCV1 was chosen as the lead candidate antibody for use in
chimpanzee studies. Three HCV-naı¨ve, healthy chimpanzees were
challenged with 32 chimp infectious doses (CID) of HCV genotype
1a strain H77. Thirty minutes prior to infusion with the HCV
challenge, chimpanzee #2 received a single intravenous infusion
of 50 mg/kg HCV1 and chimpanzee #3 received a single
intravenous infusion of 250 mg/kg HCV1. Chimpanzee #1 did
not receive HCV1 and served as the untreated control. It is
important to note that the viral inoculum was not pre-incubated
with HCV1 antibody ex vivo. Figure 2A is a schematic
representation of the sampling and testing performed over the
first 42 days of the 20 week study. HCV RNA in the chimpanzee
sera was measured using RT-PCR with a lower limit of
quantification (LLQ) equal to 500 genome equivalents (Ge)/ml.
Infusion with HCV1 at both 50 mg/kg and 250 mg/kg was well
tolerated and no infusion-related reactions were observed. There
were no significant changes in hematology, serum chemistries or
urinalysis following HuMAb infusion (data not shown). Viral load
measurements demonstrated that chimpanzee #1 (untreated
control) and chimpanzee #2 (50 mg/kg HCV1) were infected
with HCV by 14 days after challenge (Figure 2B). HCV RNA
was not detected in chimpanzee #3 (250 mg/kg) during the initial
42 days shown in Figure 2B and remained below the limit of
detection for the duration of the study (140 days) at which time the
experiment was terminated. The serum concentration of HCV1
was determined at multiple time points in chimpanzee #3 using
an ELISA specific for E2 amino acids 412–423 and the terminal
half-life of HCV1 was estimated to be 11.7 days. These results
demonstrate that HCV1 was able to prevent initial HCV infection
in one chimpanzee dosed with 250 mg/kg but was not protective
in another chimpanzee given 50 mg/kg.
To determine if the treatment failure of the chimpanzee that
received 50 mg/kg HCV1 was due to mutation in the viral
envelope glycoprotein that provided resistance to HCV1, we
employed RT-PCR to amplify and sequence the entire E1/E2
envelope glycoprotein coding region from HCV RNA in the
serum of untreated chimpanzee #1 at 21 days after viral challenge
and from the 50 mg/kg-treated chimpanzee #2 at 35 days after
viral challenge. Different days were chosen for viral sequencing
based on the availability of serum samples. A minimum of 8
distinct viral clones from each infected chimpanzee were
sequenced and compiled. The derived sequences were translated
and the amino acid sequences were compared to the consensus
amino acid sequence present in the viral inoculum (H77 genotype
1a). For each chimpanzee #1 and #2, only three amino acid
positions were altered from that of the HCV H77 genotype 1a
virus (Table 1). Both the untreated chimpanzee #1 and the
50 mg/kg-treated chimpanzee #2 had no alterations in amino
acids 412–423 when compared to the consensus H77 sequence.
Untreated chimpanzee #1 had 3 positions, 394, 434 and 444, that
were divergent from the H77 consensus sequence. Treated
chimpanzee #2 also had three amino acid positions that did not
match those found in the H77 consensus sequence and was
different than those in chimpanzee #1, residues 391, 401 and 608.
Based on the epitope of HCV1, none of the sequence alterations
found in either chimpanzee #1 or chimpanzee #2 were predictive
of HCV1-resistant virus.
To determine if the lack of virologic control in chimpanzee #2
correlated with resistance to neutralization, lentiviral pseudovirus
was generated. This was accomplished by co-transfection of HEK-
293T/17 cells with the E1/E2 sequences from the untreated
chimpanzee #1 or the 50 mg/kg-treated chimpanzee #2 and the
lentiviral backbone with a defective native glycoprotein gene and
an engineered luciferase reporter gene (HCVpp). HCVpp was
harvested from the culture supernatants, concentrated and stored
frozen in aliquots. Varying dilutions of HCV1 were incubated with
pseudovirus from chimpanzee #1 (day +21) and chimpanzee #2
(day +35), CHP1+21–HCVpp and CHP2+35–HCVpp, respec-
tively, and HCV1 neutralization capacity assessed. HCV1 was
able to neutralize both CHP1+21–HCVpp and CHP2+35–
HCVpp equivalently to H77–HCVpp (data not shown). These
data demonstrate that the inability of HCV1 to protect
chimpanzee #2 from infection was not due to HCV1-resistant
virus.
HCV1 neutralizes HCV in an acutely-infected chimpanzee
To determine if HCV1 has the capacity to treat an acutely-
infected animal, the untreated control chimpanzee #1 was
administered 250 mg/kg HCV1 42 days following initial infection
with 32 CID H77 virus. Viral load was measured at day +49 and
HCV could not be detected in the serum (Figure 3). At day +56,
two weeks following HCV1 administration, viral load was found to
have rebounded and continued to persist through day +72, at
which time the chimpanzee naturally cleared the virus (Figure 3).
These results suggest that HCV1 provided strong neutralizing
activity in the setting of recent infection and it is worth noting that
Figure 1. HuMAb HCV1 blocks E2 binding to CD81 LEL. Varying
concentration of HCV1 (blue diamonds) or irrelevant human antibody
(red squares) were incubated with a constant concentration of E2660
and subsequently applied to CD81 LEL-coated to ELISA plates. Binding
of E2660 to CD81 LEL was detected using an anti-(His)6 antibody and the
percent inhibition as compared to no antibody plotted.
doi:10.1371/journal.ppat.1002895.g001
HCV1 Prevents and Treats HCV Infection in Chimps
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HCV1 antibody levels in the serum were still high at the time of
viral rebound (data not shown).
Given the complete suppression of circulating HCV followed by
rapid rebound of the virus in this chimpanzee we assessed whether
rebounding virus had developed resistance mutations that would
allow for viral escape from HCV1 neutralization. RT-PCR was
performed on serum samples from chimpanzee #1 on day +42
before HCV1 treatment and day +56 (two weeks following
treatment) to determine sequence changes in the viral envelope
glycoprotein gene following receipt of HCV1 antibody. The entire
E1/E2 coding region was amplified and multiple clones were
sequenced. The nucleotide sequence was translated and it was
determined that nearly all amino acids were identical between the
day +42 and day +56 sequences with the exception of position 415.
In all of the viral sequences identified at day +56, N415 had been
altered to either N415D or N415K, in equal distribution (10 of 20
sequenced clones for each mutation) (Table 2). The N415K
mutation had previously been identified in vitro and H77–HCVpp
bearing N415K E1/E2 had been shown to be resistant to HCV1
neutralization [26]. Four E2 residues, 480, 612, 615 and 618,
showed minor alterations in that the amino acid usage was mixed
at day +56 as compared to that seen at day +42 (Table 2).
To determine if the N415K/D changes resulted in resistance to
HCV1, HCVpp were generated using E1/E2 sequences from
chimpanzee #1 identified on both day +42 and day +56. As
expected HCVpp bearing envelope glycoproteins cloned from day
+42 virus (CHP1+42–HCVpp) were neutralized by HCV1
equivalently to H77–HCVpp (Table 3). In contrast, HCVpp
incorporating E1/E2 glycoproteins from day +56 virus
(CHP1+56–HCVpp) were completely resistant to HCV1 neutral-
ization even at the highest concentration of antibody tested
(1000 nM). To confirm that resistance was a result of the N415K/
D mutation in CHP1+56 E1/E2 envelope glycoprotein, site-
directed mutagenesis was performed to revert the 415 position
back to asparagine. As expected, this mutation restored sensitivity
to HCV1 neutralization (Table 3). In addition, site-directed
mutagenesis was performed to incorporate the N415K or N415D
mutation into the E1/E2 gene from the H77 isolate. Both
mutations at position 415 resulted in H77–HCVpp that were
completely resistant to HCV1 neutralization. These results
confirm that mutation at position 415 of the E1/E2 envelope
glycoprotein following treatment with HCV1 allowed the virus
present in chimpanzee #1 to escape neutralization. Of note, H77–
HCVpp containing engineered E1/E2 alterations L480H, P612L,
Figure 2. HuMAb HCV1 protects chimpanzees from initial infection with HCV. A. A schematic representation of the chimpanzee protection
study is shown. The first 42 days of the experiment are represented by the gray bar with the days of sampling listed. Viral RNA levels (red), safety labs
and HCV1 antibody levels (green) and urinalysis (blue) were measured at the time points listed below the arrows. H77 genotype 1a HCV viral
challenge (32 chimpanzee infectious doses (CID)) was administered 30 minutes following infusion with HCV1 antibody (day 0, yellow). B. Serum viral
RNA levels were measured from day 27 to day +42 post-infection using quantitative PCR and were reported as genome equivalents (Ge)/ml. The
legend denotes the dose of HCV1 (mg/kg) each chimpanzee received prior to virus infusion. The lower limit of quantification for the qPCR was 500
Ge/ml.
doi:10.1371/journal.ppat.1002895.g002
Table 1. Amino acid alterations identified in H77 HCV E1/E2 envelope glycoproteins after initial viral infection in untreated (#1)
and treated (#2) chimpanzees.
Amino Acid Position
391 394 401 412 413 414 415 416 417 418 419 420 421 422 423 434 444 608
H77 S R G Q L I N T N G S W H I N E Q M
Chimpanzee #1 (day +21) - H - - - - - - - - - - - - - D R/Y -
Chimpanzee #2 (day +35) N - S - - - - - - - - - - - - - - V
doi:10.1371/journal.ppat.1002895.t001
HCV1 Prevents and Treats HCV Infection in Chimps
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L615F or Y618F (found in virus present at day +56) were all
neutralized by HCV1 equivalently to wild–type H77–HCVpp
(data not shown).
HCV1 treatment of chronically-infected chimpanzees
Although HCV1 was able to reduce viral load to below the level
of detection in an acutely-infected chimpanzee, this protection was
not durable and resulted in the emergence of resistant virus. To
determine the efficacy of HCV1 in treating chronically-infected
chimpanzees, a single intravenous infusion of HCV1 at 40 mg/kg
was administered to three chronically-infected (.5 years) chim-
panzees (genotype 1a). This dose was the maximum allowable dose
as determined by the IACUC at the institution where this specific
study was performed. Each infusion was well tolerated and no
adverse reactions were observed. Viral load was measured during
the course of the study and the results were plotted through day
+35 in Figure 4. Two of the chimpanzees, A and C, had minor
reductions in viral load immediately following the infusion, 0.5
log10 and 1 log10, respectively. In contrast, the viral load in
chimpanzee B rapidly diminished to below the level of detection
by day +5. HCV RNA remained below the level of detection until
day +21 and returned to pre-treatment levels by day +24.
To determine if the rebound in viral load in chimpanzee B was
a result of the emergence of escape virus resistant to HCV1, the
entire E1/E2 gene from chimpanzee B at day +35 was isolated
and sequenced and compared to sequences obtained from this
same chimpanzee prior to HCV1 treatment (day 28) and the
results are shown in Table 4. 100% of the sequences identified at
day +35 had two significant alterations that were not seen in any
day 28 clones, one at position 417 (N to S) and the other at
position 444 (Q to R). The mutation N417S is within the epitope
for HCV1 (amino acids 412–423) and suggested that this
alteration may provide resistance to HCV1 neutralization.
To ascertain if the changes at position 417 and 444 conferred
resistance to HCV1 neutralization, HCVpp was generated using
E1/E2 sequence isolated from chimpanzee B at day +35
(CHPB+35–HCVpp). Varying concentrations of HCV1 were
applied to CHPB+35–HCVpp and neutralization potency deter-
mined. HCV1 was unable to neutralize CHPB+35–HCVpp at any
concentration tested demonstrating that the virus was completely
resistant to HCV1 (Table 3). A neutralizing HCV HuMAb (96-2)
directed against E2 epitope II (amino acids 432–443) was able to
neutralize this virus equivalently to H77–HCVpp (data not
shown). Also, mutation of the S417 to N417 in CHPB+35–
HCVpp restored sensitivity to HCV1 neutralization (data not
shown).
To confirm that the N417S mutation was responsible for escape
from HCV1 neutralization, we engineered this mutation into the
H77 virus E1/E2 envelope glycoprotein and generated H77N417S–
HCVpp. Interestingly, this mutation rendered the pseudovirus
non-infectious and we were initially unable to assess the impact of
this mutation on HCV1 neutralization (Table 3). Given that the
N417S and Q444R both arose in the chimpanzee upon viral
rebound we created H77 pseudovirus bearing both of these
mutations (H77N417S/Q444R–HCVpp). Addition of the Q444R
mutation to the N417S mutation restored H77–HCVpp infectivity
suggesting that the Q444R mutation was compensatory to N417S.
HCV1 was unable to neutralize H77N417S/Q444R–HCVpp at the
highest concentration tested (1000 nM, Table 3) whereas the
epitope II-specific antibody, 96-2, could potently neutralize this
HCVpp (data not shown). H77–HCVpp was also generated solely
containing the Q444R mutation (H77Q444R–HCVpp) and HCV1
neutralized this HCVpp similarly to wild type H77–HCVpp
(Table 3) suggesting that the mutation at position 444 does not
confer resistance to HCV1.
HCV1 has the capacity to neutralize HCVpp pseudotyped
with E1/E2 derived from poorly-responding chimpanzees
Since HCV1 was able to reduce virus to below the limit of
detection in chimpanzee B but did not provide robust antiviral
activity in either chimpanzee A or C, it was formally possible that
HCV1 was unable to neutralize the predominant virus in these
two chimpanzees. To test this hypothesis, E1/E2 gene sequences
were isolated from serum obtained from each of the three
chimpanzees 8 days prior to treatment with HCV1. The dominant
sequence from each chimpanzee was cloned into an expression
vector and HCVpp were pseudotyped with each synthesized
envelope glycoprotein. HCV1 was able to potently neutralize
HCVpp harboring envelope glycoprotein from all day 28
chimpanzee sequences (Table 3) suggesting that virus in all three
chimpanzees was sensitive to HCV1.
Figure 3. HCV1 reduces viral load to below the limit of
quantification in an acutely-infected chimpanzee. Chimpanzee
#1 was administered 32 CID H77 genotype 1a HCV on day 0 and
circulating virus was detected at 14 days after initial challenge. Forty-
two days following viral challenge, an infusion of 250 mg/kg HCV1 was
delivered and circulating viral titer measured by qPCR at days 27 to
+126 is shown (LLQ= 500 Ge/ml).
doi:10.1371/journal.ppat.1002895.g003
Table 2. Amino acid alterations in E1/E2 envelope glycoproteins following viral rebound in treated chimpanzee #1.
Amino Acid Position
412 413 414 415 416 417 418 419 420 421 422 423 480 612 615 618
Pre-HCV1 (day +42) Q L I N T N G S W H I N L/P P L Y
Post-rebound (day +56) - - - K/D - - - - - - - - L/H P/L L/F Y/F
doi:10.1371/journal.ppat.1002895.t002
HCV1 Prevents and Treats HCV Infection in Chimps
PLOS Pathogens | www.plospathogens.org 5 August 2012 | Volume 8 | Issue 8 | e1002895
We then examined whether the virus found in chimpanzees A
and C had developed mutations that were resistant to HCV1
neutralization shortly after treatment. We sequenced isolated
clones from each chimpanzee 8 to 10 days following HCV1
infusion. No significant alterations were found in the coding region
for E1/E2 following treatment with HCV1, and no changes were
found in the 412–423 epitope (data not shown). To demonstrate
that there were not changes that conferred resistance, we
generated HCVpp using E1/E2 isolated from chimpanzee A
and C 10 days following treatment with HCV1. HCV1 had
comparable neutralization potency against HCVpp containing
E1/E2 isolated either eight days prior or ten days following
treatment with HCV1 from both chimpanzees (data not shown).
These results suggest that HCV1-resistant virus had not developed
in the two chimpanzees with a minor reduction in viral load
following HCV1 treatment.
Serum from poorly-responding chimpanzees inhibits
HCV1 neutralization of HCVpp
Because HCV1 neutralized HCVpp from chimpanzees A and C
before and after treatment with equivalent potency, we speculated
that components of the serum, present in the chimpanzees with
low-level response to HCV1 (A and C) but not in serum from the
chimpanzee with complete response (B), inhibited HCV1 neutral-
ization. H77–HCVpp was incubated with 100 nM HCV1 or an
irrelevant human antibody in the presence of varying concentra-
tions of serum from each of the three chronically HCV-infected
chimpanzees as well as serum from an uninfected chimpanzee and
infectivity was assessed. Chimpanzee serum alone had a profound
and variable impact on H77–HCVpp infection by either
enhancing or inhibiting infection depending on the dilution used
(data not shown). To overcome the variability introduced by
serum in the assay, a ratio of infection in the presence of HCV1 as
compared to an irrelevant antibody was determined and plotted
(Figure 5A). A ratio of 1 indicates that HCV1 was unable to
neutralize HCVpp in the presence of chimpanzee serum and a
ratio approaching 0 would indicate complete neutralization of
HCVpp. When H77–HCVpp was incubated with 100 nM HCV1
(fully neutralizing concentration) in the presence of a 1:16 serum
dilution from chimpanzee A or C, the infection, expressed as a
ratio of HCV1 to irrelevant antibody, was 0.72 and 0.4
respectively demonstrating significant HCVpp infection suggesting
that HCV1 neutralization was impaired. In contrast, this ratio was
only 0.15 for serum from both the uninfected chimpanzee and
chimpanzee B, consistent with a low level of HCVpp infection,
suggesting that HCV1 was able to neutralize HCVpp effectively.
Infection in the absence of chimpanzee serum resulted in a ratio
near 0.1 (data not shown) suggesting effective HCV1 neutraliza-
tion. These data demonstrate that a component in the serum from
both chimpanzees A and C interfered with HCV1 neutralization
of H77–HCVpp and this factor is not present in the serum of
chimpanzee B or an uninfected chimpanzee.
We postulated that non-neutralizing antibody present in the
serum of chimpanzees A and C may be responsible for abrogating
the neutralizing activity of HCV1. We performed an ELISA to
measure the serum concentration of antibody directed against
soluble E2 envelope glycoprotein (E2660). E2660 was coated on
ELISA plates and varying dilutions of chimpanzee serum was
applied and detected with goat anti-human polyclonal antibody.
Plates were developed and the results plotted in Figure 5B.
Chimpanzees A and C had high serum concentrations of antibody
directed against E2660 whereas chimpanzee B had very low
antibody levels to this protein (Figure 5B). These data suggest
that endogenous antibody specific to E2 in the serum of
chimpanzees A and C may be capable of interfering with
neutralization of HCV with the HCV1 antibody and potentially
explains the differences in outcomes after treatment of the animals
with chronic infection. Alternatively, the findings may be related
to the dose of antibody given, and as was seen in the prevention
study, a higher dose of antibody could have been effective for
HCV neutralization.
Mutations at E2 amino acids 415 and 417 disrupt HCV1
binding
We previously reported that E2660 soluble glycoprotein harbor-
ing an N415K mutation produced by CHO cells in defined,
Table 3. IC50 values of HCV1 neutralization of various
chimpanzee-derived HCVpp.
Source of E1/E2 Day to HCV1 E1/E2 mutation IC50 (nM)
Chimpanzee #1 +42 - 3.6
Chimpanzee #1 +56 415K# .1000
Chimpanzee #1 +56 415D# .1000
Chimpanzee #1 +56 K415N 4.3
Chimpanzee #1 +56 D415N 3.9
H77 - - 5.4
H77 - N415K .1000
H77 - N415D .1000
Chimpanzee A 28 - 2.1
Chimpanzee B 28 - 1.6
Chimpanzee C 28 - 0.53
Chimpanzee B +35 417S# .1000
H77 - N417S Non-infectious
H77 - N417S/Q444R .1000
H77 - Q444R 2.9
#Mutation induced by treatment with HCV1, not site-directed mutagenesis.
doi:10.1371/journal.ppat.1002895.t003
Figure 4. Treatment of chronically-infected chimpanzees with
HuMAb HCV1. Three chronically-infected chimpanzees, A, B and C,
were infused with 40 mg/kg HCV1 at day 0 of the experiment.
Circulating viral titer was assessed using qPCR (LLQ= 15 IU/ml) for the
duration of the study and the results until day +35 were graphed.
doi:10.1371/journal.ppat.1002895.g004
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serum-free media (CD-CHO, Invitrogen) was bound strongly by
HCV1 yet HCV1 could not neutralize H77N415K–HCVpp [26].
This result led to speculation that HCV1 binding required amino
acid residues distant to amino acids 412–423, although we
believed this to be unlikely.
HCV1 binding to E2 harboring mutations at positions 415 and
417 and produced under various cell culture conditions was
assessed. HCVpp are typically produced from HEK-293T/17 cells
in bovine serum-containing media and we speculated that E2
glycoprotein produced in media containing serum was not
equivalent to E2660 (H77–derived) produced in defined media.
In fact, soluble glycoprotein produced in CD-CHO had signifi-
cantly different mobility than E2660 produced in serum-containing
media when analyzed by SDS-PAGE (data not shown). We
performed binding studies (ELISA) to determine if HCV1 had
differential recognition of E2660 depending on the method of
protein production. Wild-type E2660 and E2660 with an N415K
mutation (E2660–N415K) were produced from CHO cells in either
serum-containing media or serum–free CD-CHO media. The four
proteins were coated on ELISA plates and HCV1 binding at
varying concentrations assessed. HCV1 strongly bound to wild
type E2660 regardless of the type of media used to grow the E2660–
producing CHO cells (Figures 6A and 6B). HCV1 bound
strongly to E2660–N415K produced in defined media (Figure 6C)
though less well than to wild-type E2660 produced under the same
conditions. However, E2660–N415K produced from CHO cells in
serum-containing media was bound very weakly by HCV1
showing minimal binding even at 5 mg/ml (Figure 6D). Both
the anti–(His)6 specific antibody and the epitope II-specific 96-2
antibody recognized all proteins equivalently (Figure 6A–D).
These experiments were repeated using E2660–N415D and E2660–
N417S (data not shown) and we observed the same result as shown
for E2660–N415K. These data demonstrate that mutation at
amino acids 415 or 417 of the E2 envelope glycoprotein abrogate
HCV1 binding and thus neutralization capacity.
Discussion
Chronic infection with HCV leads to liver failure in 5–10% of
patients with liver transplant being the only treatment option. In
the setting of liver transplantation for chronic hepatitis C nearly all
liver allografts become infected with HCV and the long-term
survival of the graft is compromised by infection [33–39]. The
clinical course of recurrent hepatitis C is often aggressive resulting
in accelerated allograft cirrhosis and increased risk of graft failure
and death [34,40,41]. Treatment with pegylated-IFN–a and
ribavirin is often attempted, but the limited efficacy is balanced
against the significant risk of adverse events in this population
[8,42]. The first FDA-licensed HCV direct-acting antiviral agents,
boceprevir and telaprevir, are indicated for chronic HCV infection
but their tolerability profile will likely limit their use in patients that
have undergone liver transplantation. Novel, safe and efficacious
therapies to prevent HCV recurrence are needed, particularly
because of the limited supply of organs for transplantation.
Treatment during liver transplantation with human monoclonal
antibody capable of neutralizing HCV infection of the liver
allograft is an attractive potential therapy because of the favorable
tolerability profile of human monoclonal antibodies, IV adminis-
tration, and precedent of HBV neutralization during liver
transplant with human polyclonal antibodies. Because HCV does
not integrate into the host genome, viral clearance and cure should
be attainable in theory. However, past clinical and chimpanzee
experiments have given mixed results for the success of HCV
specific antibodies for prevention of infection.
The HCV1 human monoclonal antibody can potently neutralize
a broad range of HCV genotypes in the HCVpp system and
recognizes a conserved linear epitope in the E2 envelope
glycoprotein (epitope I, amino acids 412–423) [26]. Neutralization
of circulating virus with a monoclonal antibody prior to engraftment
may prevent liver infection in the transplant patient population. As a
surrogate for graft infection, we used a model of initial infection in
chimpanzees. HCV1, at doses of 50 mg/kg or 250 mg/kg, was
infused into chimpanzees 30 minutes prior to challenge with 32
CID of H77 genotype 1a virus. The chimpanzee receiving 250 mg/
kg was completely protected from HCV infection whereas the
chimpanzee receiving 50 mg/kg HCV1 was not protected. It is
unclear if the higher dose of HCV1 is required for protection from
initial infection in chimpanzees given that only one chimpanzee per
cohort was assessed. It is formally possible that HCV1 can only
protect a subset of chimpanzees from initial infection regardless of
dose and the limited number of chimpanzees tested did not allow for
statistical significance. Also, it was formally possible that the
chimpanzee that received the 250 mg/kg dose was refractory to
HCV infection; however, in subsequent experiments, this chim-
panzee was shown to be permissive to HCV genotype 1b infection
(data not shown). Sequence analysis of the virus from the
chimpanzee that received the lower dose of HCV1 did not reveal
any sequence alterations that would be predicted to resist HCV1
neutralization. In fact, the sequences identified in this chimpanzee
were nearly an exact match for the H77 consensus sequence and
any minor variation was also observed in the untreated chimpanzee.
Given the expense and ethical issues associated with chimpanzee
studies, true dose-ranging studies of HCV1 to determine a
therapeutic level were not performed.
To our knowledge, this is the first demonstration that pre-
administered antibody can protect chimpanzees from initial
infection with HCV. This study is the first report of an antibody
directed against E2 amino acids 412–423 tested in chimpanzees
and it is possible that this epitope is the appropriate target of a
protective monoclonal antibody. This is supported by the fact that
polyclonal antibody, which does not protect from initial infection
in this model, has been shown to contain very little antibody
directed against the HCV1 epitope. Another possibility is that we
delivered a higher dose of antibody than has been delivered
previously and this fact led to our success. At this time it is unclear
which of these possibilities are correct and experiments directly
Table 4. Amino acid alterations in E1/E2 envelope glycoproteins following viral rebound in treated chimpanzee B.
Amino Acid Position
330 412 413 414 415 416 417 418 419 420 421 422 423 444 610
Pre-HCV1 (day 28) A Q L I N T N G S W H I N Q N
Post-rebound (day +35) A/G - - - - - S - - - - - - R N/D
doi:10.1371/journal.ppat.1002895.t004
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comparing HCV1 to other neutralizing antibodies would need to
be performed.
The anti-viral neutralizing activity of HCV1 was also demon-
strated in acutely-infected and chronically-infected chimpanzees.
For the initially untreated chimpanzee that developed an acute
infection (chimpanzee #1), a dose of 250 mg/kg was able to
suppress viral load to an undetectable level before viral rebound
was noted 14 days following HCV1 infusion. For the chronically-
infected chimpanzees, a single dose of 40 mg/kg was able to
suppress viral titer to below the level of detection for 21 days in
one chimpanzee with the other two chimpanzees demonstrating a
0.5 and 1.0 log10 reduction in viral load within four days of
treatment. For the two chimpanzees treated with HCV1 (acutely-
and chronically-infected) in which the viral load was suppressed to
undetectable levels, escape mutations were detected in the 412–
423 E2 epitope upon viral rebound. Specifically, N417S and
N415K/D mutations were observed in 100% of the HCV
sequences isolated from the chronically-infected and acutely-
infected chimpanzee, respectively, indicating strong selective
pressure of the antibody on the virus of both responding
chimpanzees. Not surprisingly, HCV1 was unable to neutralize
N415K/D–HCVpp bearing glycoproteins derived from the
acutely-infected chimpanzee or H77–HCVpp engineered to
contain these mutations. HCV1 was also unable to neutralize
HCVpp pseudotyped with E1/E2–N417S derived from the
chronically-infected chimpanzee. Interestingly, N417S mutant
H77–HCVpp was not infectious in our culture system. However,
the introduction of the Q444R in addition to the N417S mutation
in H77–HCVpp restored infectivity and HCV1 was then unable
to neutralize this pseudovirus. The N417S mutation identified in
chimpanzee B following viral rebound was accompanied by a
Q444R mutation which presumably was compensatory to
maintain infectivity of the virus bearing this N417S mutation.
It is not clear why two of the chronically-infected chimpanzees
had an incomplete virologic response to treatment with HCV1.
Virus isolated from these two poorly-responding chimpanzees had
E1/E2 glycoprotein sequences nearly identical to the viral
sequences prior to HCV1 infusion suggesting that escape virus
did not develop in these chimpanzees. Also, HCV1 was able to
neutralize HCVpp bearing envelope glycoproteins derived from
both poorly-responding chimpanzees with a similar potency to
H77–HCVpp indicating that HCV1 had the capacity to neutralize
virus from these two chimpanzees. Interestingly, in the treatment
model of chronic infection, sera from the two poorly-responding
chimpanzees, but not the responding chimpanzee, were able to
inhibit HCV1 neutralization of H77–HCVpp. These chimpanzees
received a dose of 40 mg/kg HCV1 rather than the 250 mg/kg
used in the prevention study due to IACUC restrictions. It is
possible that a higher dose of HCV1 may have reduced the viral
load in all three chronically-infected chimpanzees rather than one
of three by overcoming the neutralization inhibition imposed by
the poorly-responding chimpanzee sera. Given previous literature
reports, the inhibition could be due to competing non-neutralizing
antibodies, serum lipoproteins, or other as yet unidentified factors.
Due to the small number of animals and the limited supply of
serum from the animals, we were not able to determine the nature
of the serum factor that inhibited the neutralization of HCVpp. It
is possible that endogenous anti-HCV antibodies directed against
epitope II of E2 may interfere with HCV1 potency. It has been
suggested that epitope II-specific antibodies in both chimpanzees
and humans inhibit epitope I-directed antibodies [43,44] though
these data have recently been challenged [45]. Using ELISA we
demonstrated that chronically-infected chimpanzees with an
incomplete virologic response to HCV1 did possess high
concentrations of anti-E2660 antibody in contrast to the low
concentrations found in the chimpanzee with complete virologic
response. It should be noted that we also performed ELISA on the
chimpanzee serum to determine the titers of epitope I- and II-
specific antibodies and none of the three chimpanzees had
appreciable antibody to these two epitopes (data not shown). If
endogenous chimpanzee non-neutralizing antibodies do interfere
with HCV1, these antibodies are most likely not directed to
Figure 5. Serum from poorly-responding chimpanzees inhibits
HCV1 neutralization of H77–HCVpp. A. Serum from the three
chronically-infected chimpanzees, collected prior to HCV1 infusion, and
serum from an uninfected chimpanzee were mixed at varying dilutions
(1:16 to 1:1024) with a constant concentration (100 nM) of HCV1 or
irrelevant human antibody. The mixture was incubated with H77
genotype 1a HCVpp and applied to Hep3B cells for 72 hours. Bright-Glo
luciferase detection reagent was used to quantitate infection of the
luciferase containing HCVpp. Light output was quantified and the
counts per second (CPS) for the HCV1 sample was divided by the CPS
for the irrelevant antibody sample for each dilution of the serum. The
CPS quotient as related to each serum dilution was plotted. A value of 1
would represent no neutralization of HCVpp with HCV1 and a value
approaching 0 would signify that HCV1 neutralized 100% of the HCVpp.
B. E2660 envelope glycoprotein ELISA was performed on varying
dilutions of chronically-infected chimpanzee serum collected prior to
HCV1 infusion. Bound antibody was detected employing goat anti-
human secondary antibody conjugated to alkaline phosphatase,
followed by development with PNPP substrate, and the absorbance
at 405 nm for each dilution was plotted.
doi:10.1371/journal.ppat.1002895.g005
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epitope II but to other regions of the envelope glycoproteins. We
were unable to deplete chimpanzee antibody from the serum and
perform HCVpp assays due to the limited supply of chimpanzee
serum from this study.
It has also been hypothesized that serum lipoproteins coating
HCV virions present in sera may interfere with epitope I-directed
antibodies such as HCV1 [46,47] though we have not been able to
reproduce these results in our laboratory (Babcock, unpublished
observations). The chimpanzees that did fully respond to HCV1
treatment would have to have differences in lipoprotein/virion
coating from the poorly-responding chimpanzees and this appears
to be unlikely. To determine the exact cause of the failure of
HCV1 to suppress viral load in 2 of 4 chimpanzees (antibody,
lipoproteins, other factors, etc.), additional experiments would
need to be performed on the chimpanzee serum; however, the
supply has been exhausted.
As HCV1 is intended for human therapeutic use, a relevant
question is if some or all sera samples from HCV-infected humans
are able to inhibit the neutralizing activity of HCV1 in HCVpp-
based assays. Therefore, we conducted experiments on sera from
multiple HCV-infected humans to assess interference with HCV1
neutralization of HCVpp (data not shown). The HCVpp neutral-
izing titers in these sera were so high that dilutions.1:1000 needed
to be employed to distinguish HCV1 activity from endogenous
neutralizing activity against HCVpp, i.e. the human sera neutral-
ized HCVpp potently which masked HCV1 neutralization. Mixed
with human serum at dilutions .1:1000, HCV1 neutralization of
HCVpp was not effected (Babcock, unpublished data). However,
chimpanzee serum inhibition was only significant at dilutions of
,1:500. As such, it is not clear if human sera contains factors that
inhibit HCV1 neutralization at dilutions,1:1000. It is possible that
human sera contains inhibiting factors similar to those present in
two of the chronically-infected chimpanzees; however, these factors
could be diluted in the setting of a liver transplant with large blood
and fluid losses and replacements or may only be relevant for the in
vitro HCVpp system.
Figure 6. HCV1 does not bind mutant E2 envelope glycoprotein produced in serum-containing medium. A vector encoding wild-type
E2660 was transfected into CHO cells grown in defined media (A) or serum-containing medium (B). In addition, a vector encoding E2660–N415K was
also transfected into CHO cells grown in defined media (C) or serum-containing media (D). All proteins were purified from culture supernatant using
nickel-affinity chromatography, quantified, assessed for purity and coated on ELISA plates. Varying dilutions of HCV1 (red circles) was applied to each
protein and binding assessed. In addition, varying dilutions of 96-2 (epitope II specific, blue squares), irrelevant antibody (blue triangles) and a mouse
antibody specific to the (His)6 tag (blue crosses) at the C-terminus of E2660 were assayed to control for protein coating and non-specific binding. For
HCV1, 96-2 and irrelevant mAb, bound antibody was detected employing goat anti–human secondary antibody conjugated to alkaline phosphatase,
followed by development with PNPP substrate, and the absorbance at 405 nm for each dilution was plotted. For the mouse anti-(His)6 antibody, goat
anti-mouse secondary antibody was used.
doi:10.1371/journal.ppat.1002895.g006
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One limitation of this study was the sole use of HCVpp as a
model in vitro system for understanding HCV1 neutralization
capacity and the impact of chimpanzee serum factors on HCV1
neutralization. Cell culture-infectious HCV (HCVcc) has been
developed which recapitulates all steps of the viral life cycle
including entry [48–50]. HCVcc have been shown to be infectious
in vivo [51] and as such are considered a more appropriate viral
infection system than HCVpp. Numerous differences exist
between HCVpp and HCVcc including, but not limited to,
envelope glycoprotein density [52], glycan incorporation [53], and
interaction with factors present in serum [52,54]. It is unclear how
these differences between HCVpp and HCVcc would impact the
current results. Clearly, the results demonstrating E2 glycoprotein
escape variants using HCVpp would be expected to repeat using
the HCVcc system. However, HCV1 neutralization capacity of
HCVpp was adversely affected by the presence of poorly-
responding chimpanzee serum. If HCVcc interact with serum
factors differently than HCVpp it is possible that we may observe a
different impact of serum on HCV1 neutralization. HCVcc may
be more resistant to HCV1 than HCVpp in the presence of
chimpanzee serum but the possibility exists that HCVcc may be
more sensitive to neutralization. In either case, further study using
HCVcc to validate and confirm the current results obtained with
HCVpp is warranted.
In the treatment study, using chronically-infected chimpanzees,
we administered a dose of 40 mg/kg HCV1 rather than the
250 mg/kg used in the prevention study due to IACUC
restrictions. It is possible that a higher dose of HCV1 may have
reduced the viral load in all three chronically-infected chimpan-
zees rather than one of three by overcoming the neutralization
inhibition imposed by the poorly-responding chimpanzee sera.
40 mg/kg was the highest dose allowed at this specific animal
facility and it is not possible to test again with higher doses of
HCV1.
We previously demonstrated that HCV1 was able to bind
peptides and bacterially-expressed fusion proteins comprising E2
amino acids 412–423. The strong binding of HCV1 to both
peptides and bacterially-expressed proteins suggests that glycosyl-
ation at positions 417 and 423 (two putative E2 glycosylation sites)
is not required for binding [26]. Interestingly, HCV1 was able to
bind soluble E2660 harboring N415K mutations even though
neutralization capacity against HCVpp bearing this same alter-
ation was lost [26]. Here we show that HCV1 is able to bind
E2660–N415K protein produced from defined medium but not
from serum-containing medium, the same media used for the
production of HCVpp. These data illuminate our previous results
and demonstrate that resistance mutations in the 412–423 epitope
do indeed abrogate HCV1 binding to E2 and likely HCVpp
produced in serum-containing media. It is unclear why E2660–
N415K produced in defined medium can be bound by HCV1, but
the altered migration of the protein in SDS-PAGE suggests E2660
is glycosylated differentially in defined medium. We speculate that
complete and appropriate glycosylation at positions 417 and/or
423 impacts the ability of HCV1 to bind E2 envelope glycoprotein
containing mutations at positions 415 and 417, but not wild-type
E2. Of note, the N417S mutation eliminates the N-linked
glycosylation site at position 417 but does introduce a potential
O-linked glycosylation site. The binding of HCV1 to E2660–
N417S produced in serum-containing media may be impacted by
this possible O-linked glycosylation. Also, differential glycosylation
of amino acids distant from amino acids 412–423 could possibly be
in proximity to the HCV1 epitope when positions 415 and 417 are
mutated disrupting HCV1 binding. Future studies of HCV1 (and
possibly other epitope I antibodies) binding and epitope mapping
should avoid the use of peptides and bacterially-produced proteins
that lack glycosylation as this may lead to erroneous results.
HCV1 effectively prevents acute HCV infection and signifi-
cantly reduces viral load to undetectable levels in a proportion of
chronically-infected chimpanzees at doses ranging from 40 mg/kg
to 250 mg/kg. A phase 1 trial in healthy adults has been
completed and HCV1 proved to be safe and well tolerated. Studies
are now in progress to examine the efficacy of HCV1 in the
prevention of HCV infection of the donor liver in the liver
transplant setting.
Materials and Methods
Ethics statement
All experiments using chimpanzees were performed in accor-
dance with the Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use
Committees at both the Southwest National Primate Research
Center at the Texas Biomedical Research Institute (Animal
Welfare Assurance Number A3082-01) and New Iberia Research
Center (Animal Welfare Assurance Number A3029-01).
Cells and cell culture
CHO-K1SV cells (Lonza) were grown in CD-CHO media
(Invitrogen) or Dulbecco’s modified eagle medium supplemented
with 10% fetal bovine serum (DMEM/FBS). HEK-293T/17 cells
(ATCC) were grown in DMEM/FBS supplemented with 100 IU
penicillin/streptomycin. CHO-K1SV cells in CD-CHO were
grown in Erlenmeyer flasks with constant orbital shaking. All cells
were cultured at 37uC in air supplemented with 5% CO2.
Antibody cloning, expression and purification
HCV1 heavy and light chain genes were cloned into a
mammalian expression vector containing a glutamine synthetase
(GS) gene as previously described [26]. CHO-K1SV cells were
electroporated with the HCV1 expression vector and transfectants
were selected using 50 mM methionine sulfoximine (MSX).
Transformants were screened for antibody expression and the
highest expressing clone (.500 mg/L) was selected for antibody
production in bioreactors. Culture supernatant from bioreactors
was clarified using centrifugation and filtration and antibody was
purified using protein A followed by ion exchange chromatogra-
phy. Antibody was formulated at 10 mg/ml in 20 mM citrate/
150 mM NaCl/0.025% Tween-80 and was determined to be
.98% antibody monomer lacking detectable endotoxin.
Antibody 96-2 is a human monoclonal antibody directed
against HCV antigenic site II (amino acids 432–443) which was
generated and characterized during the isolation of HCV1 [26].
96-2 was purified from hybridoma culture supernatant which was
incubated with protein A sepharose beads (GE Healthcare) for
2 hours at room temperature while rocking. Beads were removed
by column filtration, washed with PBS and antibody eluted with
100 mM glycine pH 2.8. Eluate was dialyzed against PBS and
concentrated using an Amicon YM-30 centriprep concentrator as
described by the manufacturer. Purified antibody was filter
sterilized and protein concentration determined by spectropho-
tometry.
Anti-(His)6 monoclonal antibody is a mouse monoclonal
antibody that was developed in house and purified from
hybridoma supernatants as described above.
Prevention study in chimpanzees
Chimpanzees were maintained in accordance with the Guide for
the Care and Use of Laboratory Animals at the Southwest National
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Primate Research Center at the Texas Biomedical Research
Institute (Animal Welfare Assurance Number A3082-01). The
protocol (#1070 PT0) was approved by the center’s Institutional
Animal Care and Use Committee. Healthy female chimpanzees
were untreated or infused with 50 mg/kg or 250 mg/kg HCV1
antibody 30 minutes prior to inoculation with 32 chimp infectious
doses (32 CID) of H77 genotype 1a HCV serum [31,32]. Animals
were followed for a total of 20 weeks following delivery of the
HCV inoculum. Serum samples were obtained at varying time
points to measure viral load using a TaqMan assay as well as
HCV1 serum concentration using ELISA. In addition, clinical and
safety laboratory testing was performed throughout the study (20
weeks).
Treatment study in chimpanzees
Chimpanzees were housed and maintained according to the
Guide for the Care and Use of Laboratory Animals at the New Iberia
Research Center (Animal Welfare Assurance Number A3029-01).
The protocol (#2011-8741-027) was approved by the center’s
Institutional Animal Care and Use Committee. IACUC approval
restricted HCV1 dosing to 40 mg/kg in this study. Three female
chimpanzees, chronically infected with H77 genotype 1a HCV,
were infused intravenously with 40 mg/kg HCV1 over one hour.
Chimpanzees were followed for 35 days with blood samples
collected for safety labs (hematology and serum chemistries). Viral
load (quantitative PCR – lower limit of quantification of 15 IU/
ml) and circulating antibody concentration (ELISA) to E2 amino
acids 412–423 were measured at multiple time points during the
five week study period.
Sequencing of HCV E1/E2 DNA from chimpanzee serum
The RNeasy kit (Qiagen) was employed following the manu-
facturer’s instructions to isolate RNA from 100 ml to 1 ml of serum
and purified RNA was stored as frozen aliquots. RT-PCR was
performed on 3 ml of isolated RNA using the Superscript III One-
Step RT-PCR System with Platinum Taq (Life Technologies) as
described by the manufacturer. The forward oligonucleotide
consisted of a 59 overhang and HindIII site followed by a sequence
corresponding to a region upstream of the E1 coding region (59–
GCT TAG CAA GCT TCG CCG ACC TCA TGG GGT ACA
TAC CGC TCG 239). The reverse oligonucleotide incorporated
a 59 overhang and XbaI site followed by a sequence complimen-
tary to the terminal coding region of E2 (59– CGC TTG CTC
TAG ACG AGG TTC TCC AAA GCC GCC TCC GCT TGG
239). The resulting RT-PCR product, consisting of 1891 base
pairs, was digested with HindIII and XbaI and ligated to
pcDNA3.1 (Invitrogen). DH5a Escherichia coli cells were trans-
formed with the ligation reaction, plated to LB agar plates
containing ampicillin, grown overnight at 37uC and colonies were
assessed for E1/E2 PCR product incorporation. Positive clones (5–
15 total) were sequenced by the Sanger method and analyzed
using Vector NTI software.
E1/E2 and E2660 cloning and mutagenesis
Prototypical genotype 1a E1/E2 envelope glycoprotein genes
were amplified from an H77 expression plasmid (p90HCVcon-
sensuslongpU) obtained through the AIDS Research and Refer-
ence Program, Division of AIDS, NIAID, NIH from Dr. Charles
M. Rice via Apath, LLC. The PCR product contained 59 HindIII
and 39 XbaI restriction sites and were cloned into pcDNA3.1
containing a 39 (His)6 epitope tag. H77 soluble E2660 was cloned,
expressed and purified as previously described [26].
To create expression constructs of E1/E2 isolated from
chimpanzee serum, a forward primer (E1F1) containing a 59
HindIII site, Kozak sequence and start codon followed by
sequence complimentary to 59 end of the E1 gene was designed
(59– GAT GAG CAA AGC TTG CCG CCA CCA TGG CCA
CCG GCA ACC TGC CCG GCT G 239). A reverse primer,
E2R1, containing a 59 XbaI site followed by sequence compli-
mentary to the 39 end of the E2 gene was also synthesized (59–
GCA TTC ACT CTA GAC GCC TCC GCC TGG GAG ATC
AGC 239). PCR with primers E1F1 and E2R1 using template
consisting of cloned PCR products in pcDNA3.1 obtained during
the sequencing of virus from chimpanzee serum was performed.
Cloned E1/E2 was sequenced and confirmed.
Mutagenesis of the full-length E1/E2 and E2660 expression
plasmids was performed using the Quick Change II Site-Directed
Mutagenesis kit (Stratagene) following the manufacturer’s instruc-
tions. Following mutagenesis the E1/E2 encoding region was
sequenced to confirm the introduction of the desired mutation as
well as integrity of the entire coding sequence.
CD81 blocking assay
RNA was extracted from HEK-293T/17 cells using the RNeasy
kit (Qiagen) as described by the manufacturer. RT-PCR was
employed to amplify nucleotides 342 to 600 of the CD81 gene
which encodes for the CD81 large extracellular loop (LEL). The
amplicon was cloned into pGEX-6P (GE Healthcare) in frame
with the N-terminal glutathione S-transferase (GST) and C-
terminal myc epitope tag and expressed in BL-21 E. coli. Bacteria
were lysed and the protein purified using glutathione sepharose
chromatography. Purified CD81 LEL-GST was cleaved with
PreScission protease to remove the GST tag and CD81 LEL was
isolated by size-exclusion chromatohgraphy. Purified CD81 LEL
(1 mg/ml) was coated on ELISA plates overnight at 4uC and
subsequently washed. E2660 containing a C-terminal (His)6 tag
(5 mg) was incubated with varying concentrations of HCV1 or an
irrelevant human antibody for 1 hour at room temperature.
Complexes were added to the CD81 LEL-coated ELISA plate and
incubated for 1 hour at room temperature. E2660 binding was
detected using an anti-(His)6 followed by goat anti-mouse IgG -
alkaline phosphatase (AP) conjugate (1:5000, Jackson Immunor-
esearch) and developed with p-nitrophenyl phosphate disodium
salt (PNPP) at 1 mg/ml in 1 M diethanolamine. Absorbance
(405 nm) was analyzed using Molecular Devices Emax plate
reader with the Softmax software.
ELISA
Chimpanzee serum and purified HCV1 was assessed for H77–
E2660 (mutant or wild-type) binding using ELISA. 96-well
microtiter plates were coated with 0.5–2 mg/ml of E2660 in PBS
overnight at 4uC. 100 ml chimpanzee serum at varying dilutions
was added to the wells and incubated at 22uC for 2 hours.
Antibody binding was detected using an anti-human IgG-AP
conjugate (1:5000, Jackson Immunoresearch) followed by PNPP at
1 mg/ml in 1 M diethanolamine. Absorbance (405 nm) was
analyzed using Molecular Devices Emax plate reader with the
Softmax software.
HCVpp neutralization assays
Pseudovirus was generated employing an HIV backbone that
contained a mutation to prevent HIV envelope glycoprotein
expression and a luciferase gene to direct luciferase expression in
target cells (pNL4-3.Luc.R-E-) [55], obtained through the AIDS
Research and Reference Program, Division of AIDS, NIAID,
NIH from Dr. Nathaniel Landau. HCV E1/E2 glycoproteins
were provided in trans by co-transfection of HEK-293T/17 cells
with pcDNA-E1/E2-H77-1a (prototypical H77 sequence) or
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pcDNA-chimp-E1/E2 (E1/E2 from chimpanzee serum) with
pNL4-3.Luc.R-E-. Supernatant containing virus particles was
harvested 48 to 72 hrs post-transfection, concentrated using
Centricon 70 concentrators, aliquoted and stored frozen at
280uC. Pseudovirus was pre-incubated with varying concentra-
tions of antibody for 1 hr at room temperature before adding to
Hep3B cells. After incubation for 72 hrs, infection was quantitated
by luciferase detection with BrightGlo luciferase assay (Promega)
and read in a Victor3 plate reader (Perkin Elmer) for light
production.
For HCVpp assays to measure chimpanzee serum inhibition of
HCV1 neutralization the above procedure was employed with
minor modifications. HCVpp were pre-incubated with 100 nM
HCV1 or irrelevant human antibody in the presence or absence of
varying concentrations of chimpanzee serum for 1 hr at room
temperature before adding to Hep3B cells. Light output was
quantified for both irrelevant antibody and HCV1 at each
concentration of chimpanzee serum and the ratio of light output
of HCV1 to irrelevant mAb samples was determined.
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